Recombinant Cynomolgus TRAIL R2 (C-6His)

Description

EnkiLife provides the Recombinant Cynomolgus TRAIL R2 (C-6His) protein,aslo know as Tumor Necrosis Factor Receptor Superfamily Member 10B,Death Receptor 5,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRAIL Receptor 2,TRAIL-R2,CD262,TNFRSF10B,DR5,KILLER,TRAILR2,TRICK2,ZTNFR9, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Cynomolgus TNF-Related Apoptosis-Inducing Ligand Receptor 2 is produced by our Mammalian expression system and the target gene encoding Ile58-Ser212 is expressed with a 6His tag at the C-terminus.Accession:A0A2K5TXK0. Expression Host:Human cells.Species:Cynomolgus.Predicted Molecular Mass:18 KDa. Background:TNFRSF10B is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. The adapter molecule FADD recruits caspase-8 to the activated receptor and is required for the apoptosis mediated by TNFRSF10B. TNFRSF10B is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. This single-pass transmembrane protein contains two cysteine-rich repeat units in its extracellular region, followed by a transmembrane segment and a cytoplasmic tail containing a typical “death domain”. TNFRSF10B expression is regulated by the tumor suppressor p53. It is also indicated that the activation of NF-kappa-B can be promoted by TNFRSF10B.